Want to see BLGO full AI Analyst Report?
BLGO Stock Chart & Stats
$0.19
<$0.01(0.17%)
At close: 4:00 PM EST
$0.19
<$0.01(0.17%)
Day’s Range― - ―
52-Week Range$0.10 - $0.23
Previous CloseN/A
Volume222.28K
Average Volume (3M)570.01K
Market Cap
$35.46M
Enterprise Value$36.83M
Total Cash (Recent Filing)$4.12M
Total Debt (Recent Filing)$5.66M
Price to Earnings (P/E)―
Beta-0.33
Next Earnings
Aug 18, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding320,883,270
10 Day Avg. Volume632,227
30 Day Avg. Volume570,010
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)14.00
Price to Sales (P/S)7.29
P/FCF Ratio-6.78
Enterprise Value/Market Cap1.04
Enterprise Value/Revenue6.56
Enterprise Value/Gross Profit15.50
Enterprise Value/Ebitda-2.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)$3.60M
Bulls Say, Bears Say
Bulls Say
Commercialization & PartnershipsConcrete product deployments and channel deals show the company is moving technologies from R&D into revenue-generating commercial stages. Municipal PFAS installation and international distribution broaden addressable markets and validate offerings, improving long-term scaling and recurring project prospects.
Solid Unit Economics (gross Margin)Healthy gross margins indicate underlying product-level profitability and attractive unit economics. With consistent margins, the business can achieve operating leverage as revenue scales, making path-to-profitability feasible if the company accelerates top-line growth and improves fixed-cost absorption.
Flexible Equity Financing BackstopA committed financing facility provides durable capital optionality and runway without debt covenants. Management control over draw timing reduces liquidity shock risk and supports multi-stage commercialization and pilot deployments while the company pursues partnerships and channel expansion.
Bears Say
Steep Revenue Decline And Large LossesRevenue contraction alongside outsized operating and net losses signals a structural scale problem: current sales cannot cover fixed and operating costs. Persistently wide losses erode capital, hinder reinvestment, and make achieving sustainable profitability dependent on sustained top-line recovery and execution.
Severe Cash BurnHigh negative operating and free cash flow means losses are translating into real cash outflows, not just accounting items. Ongoing cash burn constrains operational flexibility, forces reliance on external funding, and raises execution risk for multi-quarter commercialization and pilot-to-scale transitions.
Compressed Equity Base And Dilution RiskA reduced equity base limits balance-sheet shock absorption and increases sensitivity to further capital raises. Reliance on equity backstops and repeated issuances risks meaningful dilution, which can impair long-term shareholder value and complicate financing of growth initiatives without improving underlying cash generation.
BioLargo News
BLGO FAQ
What was BioLargo Inc’s price range in the past 12 months?
BioLargo Inc lowest stock price was $0.10 and its highest was $0.23 in the past 12 months.
What is BioLargo Inc’s market cap?
BioLargo Inc’s market cap is $35.46M.
When is BioLargo Inc’s upcoming earnings report date?
BioLargo Inc’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were BioLargo Inc’s earnings last quarter?
BioLargo Inc released its earnings results on May 20, 2026. The company reported -$0.007 earnings per share for the quarter, beating the consensus estimate of -$0.01 by $0.003.
Is BioLargo Inc overvalued?
According to Wall Street analysts BioLargo Inc’s price is currently Overvalued.
Does BioLargo Inc pay dividends?
BioLargo Inc does not currently pay dividends.
What is BioLargo Inc’s EPS estimate?
BioLargo Inc’s EPS estimate is -0.01.
How many shares outstanding does BioLargo Inc have?
BioLargo Inc has 320,883,270 shares outstanding.
What happened to BioLargo Inc’s price movement after its last earnings report?
BioLargo Inc reported an EPS of -$0.007 in its last earnings report, beating expectations of -$0.01. Following the earnings report the stock price went up 3.636%.
Which hedge fund is a major shareholder of BioLargo Inc?
Currently, no hedge funds are holding shares in BLGO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioLargo Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.75%
12-Months-Change
Fundamentals
Return on Equity
-244.01%
Trailing 12-Months
Asset Growth
-18.51%
Trailing 12-Months
Company Description
BioLargo Inc
BioLargo, Inc. pioneers the invention, development, and commercialization of sophisticated platform technologies. The company is dedicated to tackling critical environmental challenges, such as per- and polyfluoroalkyl substances (PFAS) contamination, advanced water and wastewater purification, managing industrial odors and volatile organic compounds (VOCs), enhancing air quality, and controlling infections. Backed by numerous issued patents, BioLargo maintains a robust product pipeline and extends its expertise through comprehensive environmental engineering services. Among its notable innovations are the Advanced Oxidation system, a water treatment solution generating potent oxidative and energetic iodine species; the Aqueous Electrostatic Concentrator, specifically designed for eliminating PFAS from water; CupriDyne Clean industrial products, which effectively neutralize stubborn odors and VOCs across various industrial settings; and specialized advanced wound care products. Established in 1991, BioLargo, Inc. is headquartered in Westminster, California.
BLGO Company Deck
BLGO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call balanced notable commercialization and validation milestones (Clyra launch and clinical data, AEC municipal install with EPA monitoring, Cellinity MOUs and technology validation, service revenue doubling, and preserved cash) against material near-term financial challenges (2025 revenue decline to $7.8M, $15.2M net loss, a booked credit loss, Pooph license termination and litigation, and diminished shareholders' equity). Management emphasizes transition from development to commercialization and several near-term catalysts for 2026, but the significant 2025 financial deterioration and ongoing legal/partner risks temper the outlook.View all BLGO earnings summariesTechnical Analysis
Ownership Overview
13.03% Insiders
0.04% Other Institutional Investors
86.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---